Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
More about this company
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Sector: health
Conviction from: NASDAQ
52-week range: 14.7234.19
2 tracked filer(s) hold this · 1 opened, 0 added, 0 trimmed in 30-JUN-2026
Aggregate 13FScore 48 — mean of 2 scored holder(s) · buyers (new/add) avg 63. Higher = the smart money in this name has the better track record.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-01-20 | SCHEDULE 13D | EcoR1 Capital, LLC | 9.1% | Med | filing |
| 2026-01-20 | SCHEDULE 13D | MPM BIOVENTURES 2018, L.P. | 19.3% | Med | filing |
| 2026-01-15 | SCHEDULE 13D | ELI LILLY & Co | 11.9% | Med | filing |
| 2026-01-14 | SCHEDULE 13D | VV Manager II, LLC | 10.9% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-01-14 | Foley Todd (cluster of 6) | director+10%-owner | 232,870 | $4,191,660 | Form 4 |
| 2026-01-14 | MPM ONCOLOGY INNOVATIONS FUND LP (cluster of 6) | 10%-owner | 1,112,777 | $20,029,986 | Form 4 |
| 2026-01-14 | GADICKE ANSBERT (cluster of 6) | 10%-owner | 1,112,777 | $20,029,986 | Form 4 |
| 2026-01-12 | Kim Helen Susan (cluster of 6) | director+10%-owner | 835,000 | $15,030,000 | Form 4 |
| 2026-01-12 | VIDA VENTURES II-A, LLC (cluster of 6) | 10%-owner | 835,000 | $15,030,000 | Form 4 |
| 2026-01-12 | NODELMAN OLEG (cluster of 6) | director | 2,222,222 | $39,999,996 | Form 4 |